1-5 of 5
Hebing Zhou
Close
Sort by
Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Huixing Zhou, Long Chang, Jing Jia, Jie Ma, Hua Xue, Hao Li, Wenrong Huang, Hebing Zhou, Jingnan Sun, Liping Su, Yanping Ma, Huang Hongming, Hongmei Jing, Zhenling Li, Guangyu Ma, Guohong Su, Jihao Zhou, Biyun Chen, LI Bao, Zhihua Zhang, Lin Yang, Haiping Yang, Yanhong Zhao, Chunyan Sun, Qingming Wang, Qimuge Saiyin, Da Gao, Xiaoxia Chu, Zhenfang Xi, Weiwei Tian, Xuliang Shen, Shi Minxia, Jin Zhang, Yi Chen, Jingbo Xu, Yao Liu, Hongling Peng, Weijun Fu, Jun Luo, Zhenyu Li, Hui-Han Wang, Xiaobo Wang, Xiuli Sun, Jinqiao Zhang, Wei WANG, Yan Yan, Yafei Wang, Xin Du, Yonghuai Feng, Yi Wang, Ying Sun, Liye Zhong, Li Gao, Wenming Chen, Jian Li, Wen Gao
Journal: Blood
Blood (2023) 142 (Supplement 1): 4754.
https://doi.org/10.1182/blood-2023-180736
Published: 2023
Journal Articles

Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

Peng Zhao, Zhuoyu An, Haixia Fu, Daihong Liu, Liping Dou, Yi Liu, Hui Liu, Zhao Wang, Yujun Dong, Hongmei Jing, Hebing Zhou, Zhen-Ling Li, Lihong Li, Qiu-Sha Huang, Jin Wu, Yejun Wu, Chen-Cong Wang, Xiaolu Zhu, Qi Chen, Yun He, Kaiyan Liu, Xiaohui Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1207.
https://doi.org/10.1182/blood-2023-181622
Published: 2023
Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients： the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Shaoling Wu, Lijun Mu, Hai Lin, Hebing Zhou, Hong-Xia Shi, Jinghua Wang, Hongmei Jing
Journal: Blood
Blood (2023) 142 (Supplement 1): 4578.
https://doi.org/10.1182/blood-2023-188037
Published: 2023
Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Yuan Jian, Long Chang, Mingxia Shi, Ying Sun, Xiaoxia Chu, Hua Xue, Wenrong Huang, Xuliang Shen, Jie Ma, Guorong Jia, Yaqing Feng, Zhenfang Xi, Yanhong Zhao, Yanping Ma, Jing Xiao, Guangyu Ma, Qingming Wang, Li Bao, Yujun Dong, Hebing Zhou, Chunyan Sun, Guohong Su, Yan Yan, Saiyin Qimuge, Liping Su, Jingnan Sun, Weiwei Tian, Xiuli Sun, Hongmei Jing, Da Gao, Wenming Chen, Jian Li, Wen Gao
Journal: Blood
Blood (2022) 140 (Supplement 1): 10167–10169.
https://doi.org/10.1182/blood-2022-159361
Published: 2022
Journal Articles

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Li Bao, Min-qiu Lu, Peng Liu, Yu-Tong Wang, Junling Zhuang, Mei Zhang, Zhongjun Xia, Zhenling Li, Ying Yang, Zhenyu Yan, Hongmei Jing, Wenming Chen, Hebing Zhou, Rong Fu, Yuping Gong, Wenrong Huang, Yongqing Zhang
Journal: Blood
Blood (2022) 140 (Supplement 1): 12564–12565.
https://doi.org/10.1182/blood-2022-168068
Published: 2022